Telaprevir and ribavirin interaction: higher ribavirin levels are not only due to renal dysfunction during triple therapy

• Published in: Antimicrobial agents and chemotherapy 2015-06, Vol.59 (6), p.3257-3262
• Main Authors: Gutierrez-Valencia, Alicia, Ruiz-Valderas, Rosa, Ben-Marzouk-Hidalgo, Omar J, Torres-Cornejo, Almudena, Espinosa, Nuria, Castillo-Ferrando, Juan R, Viciana, Pompeyo, Lopez-Cortes, Luis F
• Format: Article
• Language: English
• Subjects: Adult; Antiviral Agents; Antiviral Agents - pharmacokinetics; Antiviral Agents - therapeutic use; Coinfection - blood; Coinfection - drug therapy; Creatinine - blood; Drug Therapy, Combination; Female; Hepatitis C virus; Hepatitis C, Chronic; Hepatitis C, Chronic - blood; Hepatitis C, Chronic - drug therapy; HIV Infections; HIV Infections - blood; HIV Infections - drug therapy; Human immunodeficiency virus; Humans; Interferon-alpha; Interferon-alpha - pharmacokinetics; Interferon-alpha - therapeutic use; Male; Middle Aged; Oligopeptides; Oligopeptides - pharmacokinetics; Oligopeptides - therapeutic use; Ribavirin; Ribavirin - pharmacokinetics; Ribavirin - therapeutic use; Tandem Mass Spectrometry
• ISSN: 0066-4804; 1098-6596
• DOI: 10.1128/AAC.04795-14

A higher incidence of anemia has been observed during the treatment of hepatitis C virus genotype 1 (HCV-1) infection with pegylated alpha interferon (pegIFN-α), ribavirin, and telaprevir. We assessed the impacts that concomitant administration of telaprevir and changes in the glomerular filtration rate have on ribavirin plasma levels. The minimum concentrations of ribavirin in plasma (ribavirin Cmin) determined during triple therapy including telaprevir were compared with those observed after telaprevir withdrawal and those observed in the same subjects and in a large cohort during a previous course of pegIFN-α plus ribavirin. Intensive pharmacokinetic sampling for ribavirin was performed at steady state during the triple-therapy phase. Ribavirin levels were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Twenty-seven HCV-1/HIV-coinfected patients were enrolled. The median ribavirin Cmin for triple therapy (4.08 μg/ml; range, 2.14 to 5.56 μg/ml) was higher than that observed after telaprevir withdrawal (1.96 μg/ml; range, 0.41 to 3.45 μg/ml) (P < 0.001) and that observed for 125 HCV-1/HIV-coinfected patients treated only with pegIFN-α plus ribavirin (1.65 μg/ml; range, 0.41 to 5.56 μg/ml) (P < 0.001). The estimated glomerular filtration rate (eGFR) decreased >20% from the baseline value in 11 of 27 patients and became normal after telaprevir removal in almost all cases. There was a negative correlation between eGFR and ribavirin clearance (r(2) = 0.257; P = 0.064) but not the ribavirin area under the concentration-time curve from 0 to 12 h (AUC0-12) (r(2) = 0.001; P = 0.455). Thus, there is a significant pharmacokinetic interaction between telaprevir and ribavirin that results in very high ribavirin levels, which explains the excess of toxicity observed with this drug combination. A blockade of the proximal tubular transporters might be implicated in both the increase in plasma creatinine and the high ribavirin levels. (This study has been registered at ClinicalTrials.gov under registration no. NCT01818856.).